<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26625877</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>06</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>03</Month>
        <Day>26</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2141</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>172</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2016</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>British journal of haematology</Title>
          <ISOAbbreviation>Br J Haematol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>How I manage Evans Syndrome and AIHA cases in children.</ArticleTitle>
        <Pagination>
          <StartPage>524</StartPage>
          <EndPage>534</EndPage>
          <MedlinePgn>524-34</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.13866</ELocationID>
        <Abstract>
          <AbstractText>The management of Evans Syndrome in children is challenging due to the lack of evidence-based data on treatment. Steroids, the first-choice therapy, are successful in about 80% of cases. For children who are resistant, relapse or become steroid-dependent, rituximab is considered a valid second-line treatment, with the exception of those with an underlying diagnosis of autoimmune lymphoproliferative syndrome who may benefit from other options such as mycophenolate mofetil and sirolimus. Better knowledge of the immunological mechanisms underlying cytopenias and the availability of new immunosuppressive drugs can be helpful in the choice of more targeted therapies that would enable the reduction of the use of long-term steroid administration or other more aggressive options, such as splenectomy or stem cell transplantation. This manuscript provides an overview of the pathogenic background of the disease, and suggests a clinical approach to diagnosis and treatment with a particular focus on the management of relapsing/resistant disease.</AbstractText>
          <CopyrightInformation>Â© 2015 John Wiley &amp; Sons Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Miano</LastName>
            <ForeName>Maurizio</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical and Experimental Haematology Unit, Department of Haematology/Oncology, IRCCS Istituto Giannina Gaslini, Genoa, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Haematol</MedlineTA>
        <NlmUniqueID>0372544</NlmUniqueID>
        <ISSNLinking>0007-1048</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013256">Steroids</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3A189DH42V</RegistryNumber>
          <NameOfSubstance UI="D000074323">Alemtuzumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>69G8BD63PP</RegistryNumber>
          <NameOfSubstance UI="D000069286">Bortezomib</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>83HN0GTJ6D</RegistryNumber>
          <NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8N3DW7272P</RegistryNumber>
          <NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>HU9DX48N0T</RegistryNumber>
          <NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>W36ZG6FT64</RegistryNumber>
          <NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536380">Evans Syndrome</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000074323" MajorTopicYN="N">Alemtuzumab</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000744" MajorTopicYN="N">Anemia, Hemolytic, Autoimmune</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069286" MajorTopicYN="N">Bortezomib</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013156" MajorTopicYN="N">Splenectomy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013921" MajorTopicYN="N">Thrombocytopenia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Evans syndrome</Keyword>
        <Keyword MajorTopicYN="N">autoimmune haemolytic anaemia</Keyword>
        <Keyword MajorTopicYN="N">autoimmune lymphoproliferative syndrome</Keyword>
        <Keyword MajorTopicYN="N">children</Keyword>
        <Keyword MajorTopicYN="N">immune thrombocytopenia</Keyword>
        <Keyword MajorTopicYN="N">immunosuppression</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26625877</ArticleId>
        <ArticleId IdType="doi">10.1111/bjh.13866</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
